Protecting the Kidneys During Contrast Imaging in People With Acute Heart Failure
Compares furosemide with saline fluids to protect kidneys during contrast scans in heart failure.
Key facts
- Who runs it
- Jin Joo Park
- Where
- Seongnam-si, South KoreaSee the site
- Trial code
- Registry title
- Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure
- Status
- Recruiting
- People taking part
- 190 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Furosemide
- 0.9 % Normal Saline
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with acute heart failure and congestion who have mildly to moderately reduced kidney function and need a contrast CT scan.
- Age
- 20 years or older
- Sex
- All sexes can join
- Disease stage
- Acute heart failure with clear signs of fluid congestion, and kidney function (eGFR) of 30-75 mL/min/1.73 m²
- Biomarker or test result
- eGFR of 30-75 mL/min/1.73 m²
Main reasons for not taking part
- Needs vasopressor medicine
- Needs dialysis or other kidney replacement treatment
- Allergy to furosemide
- Ongoing acute coronary syndrome
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Adults aged 20 years or older
- Emergency department visit/hospitalization for acute heart failure with clinical evidence of congestion
- Planned contrast-enhanced computed tomography during the index hospitalization
- Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL/min/1.73 m²
Who cannot take part
- Requirement for vasopressor therapy
- Requirement for renal replacement therapy (dialysis)
- Known allergy or hypersensitivity to furosemide
- Ongoing acute coronary syndrome
- Any condition deemed by the investigator to make participation in the study inappropriate
- Hyperkalemia (serum potassium >5.5 mmol/L)
- Uncorrected volume depletion or hyponatremia (serum sodium <130 mmol/L)
- Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Minjae Yoon, MDTaking people
About the trial
What the trial wants to find out
The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.
The 2 groups in the trial
- Standard Intravenous Saline HydrationExisting treatment, for comparison
Participants receive standard intravenous hydration with 0.9% normal saline (1ml/kg) before and after contrast-enhanced computed tomography as a conventional strategy for the prevention of contrast-induced acute kidney injury.
Treatment: 0.9 % Normal Saline
- Furosemide-Based Decongestion StrategyTreatment being tested
Participants receive intravenous furosemide to achieve sufficient diuresis (target ≥1,000 mL) as a decongestion-based strategy for renal protection before contrast-enhanced computed tomography.
Treatment: Furosemide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Contrast-Induced Acute Kidney Injury in Acute Heart Failure With Renal Dysfunction: The Kidney Protection Strategies Evaluation in Acute Heart Failure (K-PROSE)
- Plain-language title
- Protecting the Kidneys During Contrast Imaging in People With Acute Heart FailureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 16 July 2026